Efficacy and safety of pregnant women with chronic hepatitis B receiving nucleos(t)ide analogs therapy: a network meta-analysis

2020 ◽  
Author(s):  
Bo Zhu ◽  
Xiuli Chen ◽  
Fumin Feng ◽  
Erhei Dai
Keyword(s):  
Hepatitis B ◽  
Adverse Events ◽  
Pregnant Women ◽  
Meta Analysis ◽  
High Viral Load ◽  
Cochrane Library ◽  
Efficacy And Safety ◽  
B Virus ◽  
Blocking Effects ◽  
The Cochrane Library

Abstract Objective Reducing mother-to-child transmission(MTCT)of hepatitis B virus(HBV) is one of the key ways to eliminate hepatitis B. Although studies have demonstrated the effectiveness of oral nucleos(t)ide analogs(NAs),drug’s comparisons are lacking. The network meta-analysis aims to comprehensively compare and summarize the efficacy and safety of the three drugs (Lamivudine(LAM), Telbivudine(TBV) and Tenofovir(TDF)), providing a basis for drug selection. Methods A comprehensive retrieval of data was conducted from PubMed (Medline), Web of Science, the Cochrane Library, EMBASE, CNKI and SinoMed through to December 2019. We performed pair-wise meta-analysis and Bayesian network meta-analysis to compare the efficacy and safety of NAs. Results A total of 35 studies whith involving a total of 6,109 pregnant women with HBV infenction were selected. All three drugs can effectively block MTCT and improve HBV DNA suppression (p < 0.05). No significant differences were found in the occurrence of adverse events in mothers and infants.The results of the network meta analysis showed that the possibility of TBV and TDF being the best drug was 50% and 46%, the possibility of TBV and TDF being the second is the same-45%, the possibility of LAM being the worst drug is 85%. Conclusion LAM, TBV and TDF are effective in preventing MTCT of HBV in women with chronic HBV infection with high viral load. Using them does not seem to increase the probability of adverse events in pregnant women and infants. It cannot be ignored that TDF and TBV appear to show better blocking effects in clinical practice.

scholarly journals Intravenous dexmedetomidine during spinal anaesthesia for caesarean section: A meta-analysis of randomized trials

2017 ◽  
Vol 45 (3) ◽  
pp. 924-932 ◽  
Author(s):  
Zeqing Bao ◽  
Chengmao Zhou ◽  
Xianxue Wang ◽  
Yu Zhu
Keyword(s):  
Caesarean Section ◽  
Spinal Anaesthesia ◽  
Randomized Trials ◽  
Meta Analysis ◽  
Relevant Literature ◽  
Nausea And Vomiting ◽  
Cochrane Library ◽  
Control Group ◽  
Efficacy And Safety ◽  
The Cochrane Library

Objective To evaluate the efficacy and safety of spinal anaesthesia using dexmedetomidine for caesarean section. Methods PubMed, The Cochrane Library, and CNKI were searched for relevant literature. Results The incidence of nausea and vomiting in the dexmedetomidine group was significantly lower than that in the control group (OR = 0.21, 95% CI: 0.12–0.35, P < 0.00001). No difference was found in the incidence of pruritus between the two groups (OR = 1.21, 95% CI: 0.36–4.09, P = 0.76).The dexmedetomidine group had a higher incidence of bradycardia than did the control group (OR = 2.20, 95% CI: 1.02–4.77, P = 0.05). The incidence of shivering in the dexmedetomidine group was significantly lower than that in the control group (OR = 0.20, 95% CI: 0.13–0.32, P < 0.00001). The incidence of hypotension was not different between the two groups (OR = 0.88, 95% CI: 0.49–1.56, P = 0.65). Conclusion Dexmedetomidine can decrease the incidence of nausea, vomiting, bradycardia, and shivering with spinal anaesthesia during caesarean section.

scholarly journals Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials

BMJ Open ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. e047344
Author(s):  
Qingwu Wu ◽  
Lianxiong Yuan ◽  
Huijun Qiu ◽  
Xinyue Wang ◽  
Xuekun Huang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Adverse Events ◽  
Chronic Rhinosinusitis ◽  
Randomised Controlled Trials ◽  
Nasal Polyps ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Randomised Controlled

ObjectivesTo assess the efficacy and safety of omalizumab for chronic rhinosinusitis with nasal polyps (CRSwNP) and to identify evidence gaps that will guide future research on omalizumab for CRSwNP.DesignSystematic review and meta-analysis.Data sourcesA comprehensive search was performed in PubMed, Embase, Web of Science and the Cochrane Library on 13 October 2020.Eligibility criteriaRandomised controlled trials (RCTs) comparing omalizumab with placebo, given for at least 16 weeks in adult patients with CRSwNP.Data extraction and synthesisTwo independent authors screened search results, extracted data and assessed studies using the Cochrane risk of bias tool. Data were pooled using the inverse-variance method and expressed as mean differences (MDs) with 95% CIs. Heterogeneity was assessed by the χ2 test and the I2 statistic.ResultsA total of four RCTs involving 303 participants were identified. When comparing omalizumab to placebo, there was a significant difference in Nasal Polyps Score (MD=−1.20; 95% CI −1.48 to −0.92), Nasal Congestion Score (MD=−0.67; 95% CI −0.86 to −0.48), Sino-Nasal Outcome Test-22 (MD=−15.62; 95% CI −19.79 to −11.45), Total Nasal Symptom Score (MD=−1.84; 95% CI −2.43 to −1.25) and reduced need for surgery (risk ratio (RR)=5.61; 95% CI 1.99 to 15.81). Furthermore, there was no difference in the risk of serious adverse events ((RR=1.40; 95% CI 0.29 to 6.80), adverse events (RR=0.83; 95% CI 0.60 to 1.15) and rescue systemic corticosteroid (RR=0.52; 95% CI 0.17 to 1.61).ConclusionsThis was the first meta-analysis that identified omalizumab significantly improved endoscopic, clinical and patient-reported outcomes in adults with moderate to severe CRSwNP and it was safe and well tolerated.PROSPERO registration numberCRD42020207639.

The Relationship between Use of Low Molecular Weight Heparin during Pregnancy and Risk of Peripartum Adverse Events: A Meta-Analysis

2021 ◽  
Vol 8 (11) ◽  
Author(s):  
Xiaorong Y ◽  
◽  
Shan L ◽  
Shengji S ◽  
Tao S ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Adverse Events ◽  
Pregnant Women ◽  
Low Molecular Weight Heparin ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Premature Delivery ◽  
Low Molecular Weight ◽  
Significant Difference ◽  
Fetal Complications

Introduction: To summarize the trials investigated on relationship between low molecular weight heparin use during pregnancy and peripartum adverse events. Meta-analysis was performed to evaluate the effect of Low Molecular Weight Heparin (LMWH) on maternal and fetal complications. Methods: Electronic research was performed in Cochrane Library, MEDLINE and EMBASE through October 2020. The primary outcome was the incidence of maternal and fetal complications during peripartum period. RevMan 5.3 was used for data analysis. Results: 11 articles were finally included. Meta-analysis showed there was no significant difference in abortion, premature delivery, stillbirth, preeclampsia and postpartum hemorrhage events between pregnant women who used LMWH and those who not. Conclusion: Using LMWH in pregnant women does not increase pregnancy related maternal and fetal complications.

scholarly journals Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: A meta-analysis

PLoS ONE ◽  
2020 ◽  
Vol 15 (1) ◽  
pp. e0227532
Author(s):  
Baohui Fu ◽  
Yue Ji ◽  
Shouci Hu ◽  
Tong Ren ◽  
Maheshkumar Satishkumar Bhuva ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Viral Therapy ◽  
B Virus ◽  
Anti Viral Therapy

Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
pp. 85-96 ◽  
Author(s):  
Pauline Boucheron ◽  
Ying Lu ◽  
Kyoko Yoshida ◽  
Tianshuo Zhao ◽  
Anna L Funk ◽  
...  
Keyword(s):  
Systematic Review ◽  
At Risk ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Pregnant Women ◽  
Meta Analysis ◽  
B Virus

scholarly journals Robotic-Assisted vs. Open Simple Prostatectomy for Large Prostates: A Meta-Analysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Zhongyou Xia ◽  
Jinze Li ◽  
Xiaoying Yang ◽  
Hao Jing ◽  
Chao Niu ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Similar Efficacy ◽  
Prostatic Hyperplasia ◽  
Cochrane Library ◽  
Efficacy And Safety ◽  
Robotic Assisted ◽  
Simple Prostatectomy ◽  
The Cochrane Library ◽  
Large Prostate ◽  
Review Manager

Purpose: To compare the efficacy and safety of robotic-assisted simple prostatectomy and open simple prostatectomy for large benign prostatic hyperplasia.Methods: We systematically searched the Cochrane Library, PubMed, Embase, and Science databases for studies published through December 2020. Controlled trials on RASP and OSP for large prostates were included. The meta-analysis was conducted with the Review Manager 5.4 software.Results: A total of seven studies with 3,777 patients were included in the analysis. There were no significant differences in IPSS (WMD, 0.72; 95%CI: −0.31, 1.76; P = 0.17), QoL (WMD, 0.00; 95%CI: −0.39, 0.39; P &gt; 0.99), Qmax (WMD, 1.88; 95% CI: −1.15, 4.91; P = 0.22), or PVR (WMD, −10.48; 95%CI: −25.13, 4.17; P = 0.16) among patients undergoing RASP and OSP. However, compared with patients who underwent OSP, patients who underwent RASP had a shorter LOS (WMD, −2.83; 95%CI: −3.68, −1.98; P &lt; 0.001), less EBL (WMD, −304.68; 95% CI: −432.91, −176.44; P &lt; 0.001), a shorter CT (WMD, −2.61; 95%CI: −3.94, −1.29; P &lt; 0.001), and fewer overall complications (OR, 0.30; 95% CI: 0.16, 0.57; P &lt; 0.001). Nevertheless, RASP was associated with a longer OT (WMD, 59.69, 95% CI: 49.40, 69.98; P &lt; 0.001).Conclusion: The results of the current study demonstrated that RASP provided similar efficacy to those of OSP in the treatment of large prostate, while maintaining better security. Our findings indicate that RASP is a feasible and effective alternative to OSP.

Sign in / Sign up

Export Citation Format

Share Document